Skip to content
Medical Health Aged Care, Mental Health

New maps reveal the individual brain changes linked to different mental illnesses

Monash University 3 mins read

A breakthrough project mapping brain changes in nearly 1,300 people diagnosed with six different types of mental illness has revealed the extraordinary diversity of brain changes found in people with conditions like major depression and schizophrenia.

The study, published in Nature Neuroscience and led by researchers at Monash University’s Turner Institute for Brain and Mental Health and School of Psychological Sciences, used brain imaging to measure the size, or volume, of over 1000 different brain regions.

PhD student Ashlea Segal was part of the team leading research.

“Over the past few decades, researchers have mapped brain areas showing reduced volume in people diagnosed with a wide variety of mental illness, but this work has largely focused on group averages, which makes it difficult to understand what is happening in the brains of individual people,” said Ms Segal.

“For example, knowing that the average height of the Australian population is about 1.7 metres tells me very little about the height of my next-door neighbour.” 

Research team lead Professor Alex Fornito explained that the team used new statistical techniques developed by Professor Andre Marquand at the Donders Institute, Netherlands, who co-led the project, to map regions in the brain showing unusually small or large volumes in people diagnosed with either schizophrenia, depression, bipolar disorder, obsessive-compulsive disorder, attention-deficit hyperactivity disorder, or autism spectrum disorder.

“We used a statistical model to establish expectations about brain size given someone’s age and sex. We can then quantify how much an individual person’s brain volume deviates from these expectations, much like the growth charts commonly used for height and weight in paediatrics,” said Professor Fornito.

“We confirmed earlier findings that the specific brain regions showing large deviations in brain volume vary a lot across individuals, with no more than 7 per cent of people with the same diagnosis showing a major deviation in the same brain area.

“This result means that it is difficult to pinpoint treatment targets or causal mechanisms by focusing on group averages alone. It may also explain why people with the same diagnosis show wide variability in their symptom profiles and treatment outcomes.” 

The team then investigated the connectivity of the areas showing large volume deviations.

“Because the brain is a network, dysfunction in one area can spread to affect other, connected sites. We found that, while deviations occurred in distinct brain regions across different people, they were often connected to common upstream or downstream areas, meaning they aggregated within the same brain circuits,” said Ms Segal.

“It’s possible that this circuit-level overlap explains commonalities between people with the same diagnosis, such as, for example, why two people with schizophrenia generally have more symptoms in common than a person with schizophrenia and one with depression.”

The team leveraged their new approach to identify potential treatment targets for different disorders.

“We found that certain specific brain circuits were preferentially involved in some disorders, suggesting that they are potential treatment targets,” said Ms Segal.

“However, our findings suggest that these targets will only be appropriate for a subset of people. For instance, we found evidence that brain circuits linked to frontal areas were preferentially involved in depression. These circuits are commonly used as targets for non-invasive brain stimulation therapies, but our data suggest that they may only be effective targets for around a third of people.”

The approach developed by the team opens new opportunities for mapping brain changes in mental illness.

“The framework we have developed allows us to understand the diversity of brain changes in people with mental illness at different levels, from individual regions through to more widespread brain circuits and networks, offering a deeper insight into how the brain is affected in individual people,” said Professor Fornito.

For media enquiries please contact:

Tania Ewing
E: Tania.Ewing1@monash.edu 
T: 0408 378 422

More from this category

  • Medical Health Aged Care, Political
  • 08/12/2023
  • 15:35
Health Services Union

Minns ministers must stop misleading on paramedic pay

The Minns government is misleading the public with deliberately inflated figures about what paramedics are paid, as it risks mass resignation and deregistration of one of its most skilled but underpaid workforces.In a note circulated to media, the Government has claimed its pay offer would lift a first year paramedic’s take home pay from $123,594 to $137,683.This is not a figure that has been put to the HSU and nor it accurate. The offer put to the Union proposes a paltry 11.4 per cent, four year increase to the base pay of first year paramedics, from $74,364 to $82,877.The so-called…

  • Medical Health Aged Care, Political
  • 08/12/2023
  • 14:11
Health Equity Matters

Darryl O’Donnell steps down as CEO of Health Equity Matters

Health Equity Matters pays tribute to chief executive officer, Adjunct Professor Darryl O’Donnell, who is stepping down after eight impactful years leading the organisation. Health Equity Matters president, Mark Orr AM, said O’Donnell had been a transformative leader. “Darryl became chief executive at a very challenging time for the organisation. In the years since, he has worked tirelessly to enhance its stability and sustainability. This has expanded our capacity and impact. “Among his many achievements, Darryl has most recently helped shape the work of the HIV Taskforce chaired by the Hon Mark Butler MP, and the LGBTIQA+ Health Ten Year…

  • Medical Health Aged Care
  • 08/12/2023
  • 12:07
EnGeneIC

EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic

SYDNEY, Australia and NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA “Fast-Track” designation for its pancreatic cancer therapeutic. This approval underscores the potential of EnGeneIC’s unique approach to revolutionise pancreatic cancer treatment.Pancreatic ductal adenocarcinoma (PDAC) is a notoriously challenging and aggressive form of cancer, usually diagnosed in advanced stages, making curative treatment options limited.The FDA’s decision to grant “Fast-Track” status reflects the urgency and unmet medical need associated with PDAC. EnGeneIC’s EDVTM (EnGeneIC Dream Vector) has…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.